Natco Pharma Q2 results: net profit falls 61% to Rs 203 crore

Natco Pharma Limited has reported a consolidated net profit of Rs 202.6 crore for the quarter ended 30 September 2026, the second quarter of FY27, against Rs 517.9 crore in the same quarter a year earlier, a fall of 60.9%. Revenue from operations was Rs 967.3 crore, 29% lower than the Rs 1,363 crore of a year earlier but 31.6% higher than the Rs 735.2 crore of the preceding quarter, according to the Hyderabad company's filing with the National Stock Exchange on 13 November 2026. The board also declared a second interim dividend of Rs 1.25 per equity share of Rs 2 each.

What Happened

The figures are the unaudited consolidated results approved by the board on 13 November 2026 and reviewed by the statutory auditors. Against the preceding quarter, net profit was almost flat, down 1.9% from Rs 206.5 crore. Total income, which the company calls total revenue and which includes other income, was Rs 1,019.4 crore for the quarter, against Rs 1,463 crore a year earlier and Rs 794.4 crore in the preceding quarter. Earnings per share for the quarter were Rs 11.31, against Rs 28.94 a year earlier.

For the half year ended 30 September 2026, revenue from operations was Rs 1,702.5 crore against Rs 2,691.9 crore a year earlier, and profit for the period was Rs 409.1 crore against Rs 998.2 crore.

In the press release filed with the results, the company said the increase over the preceding quarter was "due to better performance in the International Formulation business", and that the fall from a year earlier was "largely attributable to lower Lenalidomide revenue in the current quarter which was partially offset by growth in the base business (including subsidiaries)". The release puts operating profit before the share of the associate at Rs 310 crore for the quarter, a margin of 30.4%, against 46.4% a year earlier.

The results include Rs 29.2 crore as the company's share of the profit of its associate, Adcock Ingram Holdings Limited of South Africa. The company said it bought an additional 13.25% in that associate during the quarter, taking its holding to 49%.

On the dividend, the filing says the record date for shareholders eligible for the second interim dividend of Rs 1.25 a share is 19 November 2026, and payment will start from 27 November 2026. An interim dividend of Rs 1.50 a share was approved for the preceding quarter at a board meeting on 14 August 2026.

What It Means

For shareholders on the register on 19 November 2026, the dividend of Rs 1.25 a share will be paid from 27 November 2026; those who hold shares in a demat account will receive it in the bank account linked to that account. The quarter's numbers are the company's own unaudited consolidated figures, and the comparison that matters is stated by the company itself: a sharp fall from a year earlier that it attributes to lower revenue from one product, and a recovery from the preceding quarter. A complaint about a listed company or a registrar can be filed with the Securities and Exchange Board of India at https://scores.sebi.gov.in.

Oquilia Data: NATCO Pharma Ltd. (NSE: NATCOPHARM)

Closes adjusted for splits and bonuses; returns exclude dividends; insider and pledge figures from BSE filings. Facts from NSE's files, not investment advice.

Full record: NATCO Pharma share price on Oquilia

Source: Company filing on NSE